File Photo: Silver Spring, headquarters of US Food and Drug Administration (FDA), Maryland has been seen on November 4, 2009.
Jason Reid | Roots
Food and Drug Administration said on Monday that it is Appointed East Biotech Executive George Tidmarsh as an agency Top drug regulator,
Tades, an assistant professor of pediatric and neonatics at the School of Medicine at Stanford University, leads one of the largest and most important divisions of FPASville FDA, reviewing the vast majority of new drug applications.
Drug evaluation and research, or centers for CDER, controls over-the-counter and prescription treatments including biological therapy and generic. CDER’s acting head, Jacqueline Korigan-Kure, Announced She was retiring in June.
Tidmarsh will step as FDA and its regulatory process Robert F. Under Kennedy Junior, there will be a large -scale turmoil. Kennedy has chased the deepening of deep employees in HHS and in some cases, brought to new employees, either a lack of relevant scientific and medical experiences or shares their doubts of the vaccine.
But there is a possibility of relief for the drug industry likely to participate in the widespread background of the industry in the industry and the development of seven-nominal drugs. His previous comments indicate that he can take a more rigorous approach to regulate drugs.
In public In April, Tadmarsh slammed the regulatory decisions made by a prominent officer out of the FDA under Kennedy, Peter Marx. Which involves supporting Quick approval Of Biogen ‘S sick Alzheimer’s Drug, Eduhelm, and overraise FDA employees to expand Approval Of Sarpta theraputics‘Duchene muscular dystrophy treatment elevidis.
Last week, FDA asked Serpta Theraputics Stop all shipments After three patients die after the failure of the liver or after a similar treatment. The company later stated that it would not be able to stop shipment to treat patients with the condition that can still run, the data show within that group “no new or changed security signs”.
Tidmarsh will probably be a saying on the FDA’s approach to that controversial quick approval process and advertisement of the drug. He served as the CEO of La Jola Pharmaceuticals and Horizon Pharma, in the latter half he established Amgen Bought it for $ 28 billion. Tidmarsh also established the Threshold Pharmaceutical, and held senior positions in other biotech companies.
FDA Commissioner Dr. Marti Makeri said in a statement, “Dr. Tadmarsh is a skillful doctor-scientist and leader whose experience spreads the full arch of drug development from the bench to bedside.” “His appointment to lead the CDER brings extraordinary scientific, regulatory and operational expertise to the agency.”
